

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/012052-2022>

Tender

Concession for Printing and Marketing of the British Pharmacopoeia

MHRA

F24: Concession notice

Notice identifier: 2022/S 000-012052

Procurement identifier (OCID): ocds-h6vhtk-0335b1

Published 9 May 2022, 5:02pm

The closing date and time has been changed to:

17 June 2022, 12:00pm

See the [change notice](#).

Section I: Contracting authority/entity

I.1) Name and addresses

MHRA

10 South Colonnade, Canary Wharf

London

E14 4PU

Contact

Alison Finn

Email

alison.finn@nibsc.org

Telephone

+44 7770234628

Country

United Kingdom

NUTS code

UKI31 - Camden and City of London

Internet address(es)

Main address

<https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency>

Buyer's address

<https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<http://health.atamis.co.uk>

Additional information can be obtained from the above-mentioned address

Applications or, where applicable, tenders must be submitted electronically via

<http://health.atamis.co.uk>

Applications or, where applicable, tenders must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<http://health.atamis.co.uk>

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Concession for Printing and Marketing of the British Pharmacopoeia

II.1.2) Main CPV code

- 79970000 - Publishing services

II.1.3) Type of contract

Services

II.1.4) Short description

The Medicines and Healthcare products Regulatory Agency (the Agency) is an Executive Agency of the Department of Health. We protect and improve the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research.

The British Pharmacopoeia (BP) is the official collection of standards for UK medicinal products and pharmaceutical substances. It is produced by the British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency, in accordance with regulation 317(1) of the Human Medicines Regulations 2012, and makes an important contribution to public health by setting publicly available standards for the quality of medicines.

The Agency requires the appointment of a Concessionaire to be responsible for the printing, publishing, distribution, marketing and selling of the BP and BAN publications.

II.1.5) Estimated total value

Value excluding VAT: £0.01

II.1.6) Information about lots

This concession is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 79824000 - Printing and distribution services
- 72413000 - World wide web (www) site design services
- 79342000 - Marketing services
- 79811000 - Digital printing services
- 79824000 - Printing and distribution services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The British Pharmacopoeia (BP) is the official collection of standards for UK medicinal products and pharmaceutical substances. It is produced by the British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency, in accordance with Regulation 317(1) of the Human Medicines Regulations 2012 and makes an important contribution to public health by setting publicly available standards for the quality of medicines.

Since 1864, the BP has been providing authoritative standards for medicinal products and pharmaceutical substances and it continues to play an important role in the standard-setting process worldwide. Now used in over 100 countries, the BP remains an essential reference for all individuals and organisations working within pharmaceutical research and development, manufacture and testing around the globe. All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are also reproduced in the BP.

The BP is published annually with three in-year updates, currently in both hardcopy and electronic formats; the latter is available as a download product as well as accessed via a single-user licence or a multi-user license arrangement. In addition, there is the requirement for the publication of the British Approved Names (BAN) which provides the official, non-proprietary, or generic names given to pharmaceutical substances, published annually.

The Agency requires the appointment of a concessionaire to be responsible for the printing, publishing, distribution, marketing and selling of the BP and BAN publications. A core part of the requirement is the provision and maintenance of a website, which operates as a portal to access the electronic formats of the BP, as well as acting as a source of added value material and a sales platform for the BP chemical reference standards, orders for which are fulfilled by the Agency. The link to the current website is <https://www.pharmacopoeia.com/>, and this web address is owned by the Agency. The

legacy publication content is available as an XML dataset with a DTD and shall be provided to the service provider.

The concessionaire would have responsibility for business development and marketing of the product, with the strategic approval of the Agency, and also shall be expected to invest in the services to deliver continuous improvement and innovation throughout the life of the contract. The concessionaire will also need to carefully manage sales and distribution of BP publications to our global user base which is currently conducted through established reseller networks.

The Agency wishes to award one concession contract to one contracting party; collaborations with other organisations to bring together the range of expertise (via sub-contracting/consortium arrangements) would be acceptable, with the concessionaire ensuring effective and seamless delivery. The appointed concessionaire shall retain the revenue from the service/sales as its fees minus the payment of agreed royalty fees to the Agency. The concessionaire shall have exclusivity on the sales of the BP and BAN. Pricing strategies shall be reviewed and agreed by both parties. This contracting approach is the same as the current set-up. We expect to award and agree a contract July 2022 to facilitate sufficient lead time for implementation and the publication of the BP2024 in August 2023.

II.2.5) Award criteria

Concession is awarded on the basis of the criteria described below:

- Criterion: Selection criteria as stated in the procurement documents

II.2.7) Duration of the concession

Duration in months

60

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III. Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

Section IV. Procedure

IV.2) Administrative information

IV.2.2) Time limit for submission of applications or receipt of tenders

Originally published as:

Date

23 May 2022

Changed to:

Date

17 June 2022

Local time

12:00pm

See the [change notice](#).

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.3) Additional information

For Suppliers to participate in the tender exercise for the Concession for Printing and Marketing of the British Pharmacopoeia contract they are required to download a Non Disclosure Agreement (NDA), sign the document and return.

Upon receipt of the signed NDA the Supplier shall be added to the Concession for Printing and Marketing of the British Pharmacopoeia ITT with full access to tender docs.

VI.4) Procedures for review

VI.4.1) Review body

MHRA/ NIBSC

EN6 3QG

London

EN6 3QG

Country

United Kingdom

Internet address

<https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency>